Aclarion (NASDAQ:ACON) Lowered to Sell Rating by Wall Street Zen

Aclarion (NASDAQ:ACON) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Aclarion Trading Up 6.9%

Aclarion stock opened at $3.27 on Friday. The stock has a 50 day moving average of $3.57 and a 200-day moving average of $5.93. Aclarion has a 52 week low of $2.34 and a 52 week high of $48.33. The stock has a market cap of $2.78 million, a P/E ratio of -0.22 and a beta of 1.44.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.